Top

Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2+/− rat model

Journals by subject

Unlock free access to practice-relevant journal articles

Join our community of medical professionals and register now to access a handpicked selection of journal articles from Springer's Medical portfolio.

Editor's Choice | Journals

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest Journal Issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Looking for something specific?

Find articles from over 500 clinical journals from Springer with the search function.

Latest issues in Internal Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Cardiology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Diabetes & Endocrinology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Neurology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Oncology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Pediatrics

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Respiratory Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

About journals on Springer Medicine

The range of medical journals on Springer Medicine is extremely diverse. It includes the current editions and archives of around 500 English-language journals from almost all medical disciplines published by Springer.

The specialist literature is usually available both online in full text and as a PDF for download. The online view is optimized in such a way that the specialist texts can be read comfortably on all screen sizes, from desktops to tablets to smartphones. We also include features to support your use of the journals for your research, such as bookmark setting.

Whether you’re interested in internal medicine, surgery, general medicine, gynecology, orthopedics, neurology, or pediatrics, there are excellent journals in almost every subject area, such as the BMC Series, Diabetologia, Breast Cancer Research, Current Obesity Reports, CNS Drugs and many others, all of which are an integral part of the everyday life of doctors across Europe.

The breadth of content from this suite of journals allows the Springer Medicine team to collect and deliver broad-ranging content across the full spectrum of medical knowledge, with a special focus on topics highlighted by these leading journals and their editorial boards and specialist authors. This guarantees a high quality of content and ensures that our readers are offered the most relevant topics in their respective specialist area.

Our experienced clinical content managers constantly monitor the needs of medical professionals to provide up-to-date reports from international congresses, expert interviews, and a range of digestible content on emerging topics in the field of medicine.

Journal of Neuroinflammation

Published in:

Open Access 01-12-2024 | Research

Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2^+/− rat model

Authors: Hugo Ramos, Josy Augustine, Burak M. Karan, Cristina Hernández, Alan W. Stitt, Tim M. Curtis, Rafael Simó

Published in: Journal of Neuroinflammation | Issue 1/2024

Abstract

Impaired function of the retinal neurovascular unit (NVU) is an early event in diabetic retinopathy (DR). It has been previously shown that topical delivery of the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin can protect against diabetes-mediated dysfunction of the retinal NVU in the db/db mouse. The aim of the present study was to examine whether sitagliptin could prevent the DR-like lesions within the NVU of the new non-diabetic model of DR, the Trpv2 knockout rat (Trpv2^+/−). For that purpose, at 3 months of age, Trpv2^+/− rats were topically treated twice daily for two weeks with sitagliptin or PBS-vehicle eyedrops. Trpv2^+/+ rats treated with vehicle served as the control group. Body weight and glycemia were monitored. Optical coherence tomography recordings, fundus images and retinal samples were obtained to evaluate sitagliptin effects. The results revealed that sitagliptin eye drops had no effect on body weight or glycemia. Vehicle-treated Trpv2^+/− rats exhibited retinal thinning and larger diameters of major retinal blood vessels, upregulation of inflammatory factors and oxidative markers, glial activation and formation of acellular capillaries. However, topical administration of sitagliptin significantly prevented all these abnormalities. In conclusion, sitagliptin eye drops exert a protective effect against DR-like lesions in Trpv2^+/− rats. Our results suggest that sitagliptin eye drops carry significant potential to treat not only early-stages of DR but also other diseases with impairment of the NVU unrelated to diabetes.

Wong TY, Cheung CM, Larsen M, Sharma S, Simó R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012. https://doi.org/10.1038/nrdp.2016.12.CrossRefPubMed

Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight. 2017;2(14):e93751. https://doi.org/10.1172/jci.insight.93751.CrossRefPubMedPubMedCentral

Simó R, Stitt AW, Gardner TW. Neurodegeneration in diabetic retinopathy: does it really matter? Diabetologia. 2018;61(9):1902–12. https://doi.org/10.1007/s00125-018-4692-1.CrossRefPubMedPubMedCentral

Simó R, Hernández C. What else can we do to prevent diabetic retinopathy? Diabetologia. 2023;66(9):1614–21. https://doi.org/10.1007/s00125-023-05940-5.CrossRefPubMedPubMedCentral

Hernández C, Bogdanov P, Corraliza L, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes. 2016;65(1):172–87. https://doi.org/10.2337/db15-0443.CrossRefPubMed

Hernández C, Bogdanov P, Solà-Adell C, et al. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes. Diabetologia. 2017;60(11):2285–98. https://doi.org/10.1007/s00125-017-4388-y.CrossRefPubMed

Simó R, Bogdanov P, Ramos H, Huerta J, Simó-Servat O, Hernández C. Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes. Biomedicines. 2021;9(8):926. https://doi.org/10.3390/biomedicines9080926.CrossRefPubMedPubMedCentral

McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr Rev. 2021;42(2):101–32. https://doi.org/10.1210/endrev/bnaa032.CrossRefPubMed

Bogdanov P, Ramos H, Valeri M, et al. Minimum effective dose of DPP-4 inhibitors for treating early stages of Diabetic Retinopathy in an experimental model. Biomedicines. 2022;10(2):465. https://doi.org/10.3390/biomedicines10020465.CrossRefPubMedPubMedCentral

10.

Ramos H, Bogdanov P, Sabater D, et al. Neuromodulation Induced by Sitagliptin: a New Strategy for Treating Diabetic Retinopathy. Biomedicines. 2021;9(12):1772. https://doi.org/10.3390/biomedicines9121772.CrossRefPubMedPubMedCentral

11.

Ramos H, Bogdanov P, Simó R, Deàs-Just A, Hernández C. Transcriptomic analysis reveals that retinal neuromodulation is a relevant mechanism in the neuroprotective effect of Sitagliptin in an experimental model of Diabetic Retinopathy. Int J Mol Sci. 2022;24(1):571. https://doi.org/10.3390/ijms24010571.CrossRefPubMedPubMedCentral

12.

Ramos H, Bogdanov P, Huerta J, Deàs-Just A, Hernández C, Simó R. Antioxidant effects of DPP-4 inhibitors in early stages of Experimental Diabetic Retinopathy. Antioxid (Basel). 2022;11(7):1418. https://doi.org/10.3390/antiox11071418.CrossRef

13.

Lampert A, Bruckner T, Haefeli WE, Seidling HM. Improving eye-drop administration skills of patients - A multicenter parallel-group cluster-randomized controlled trial. PLoS ONE. 2019;14(2):e0212007. https://doi.org/10.1371/journal.pone.0212007.CrossRefPubMedPubMedCentral

14.

Chung YR, Ha KH, Kim HC, Park SJ, Lee K, Kim DJ. Dipeptidyl Peptidase-4 inhibitors versus other antidiabetic drugs added to Metformin Monotherapy in Diabetic Retinopathy Progression: a Real World-based Cohort Study. Diabetes Metab J. 2019;43(5):640–8. https://doi.org/10.4093/dmj.2018.0137.CrossRefPubMedPubMedCentral

15.

Taylor OM, Lam C. The Effect of Dipeptidyl Peptidase-4 inhibitors on Macrovascular and Microvascular complications of Diabetes Mellitus: a systematic review. Curr Ther Res Clin Exp. 2020;93:100596. https://doi.org/10.1016/j.curtheres.2020.100596.CrossRefPubMedPubMedCentral

16.

Tang H, Li G, Zhao Y, et al. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis. Diabetes Obes Metab. 2018;20(5):1262–79. https://doi.org/10.1111/dom.13232.CrossRefPubMed

17.

Fuchs H, Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos. 2009;30(5):229–40. https://doi.org/10.1002/bdd.662.CrossRefPubMed

18.

Fura A, Khanna A, Vyas V, et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos. 2009;37(6):1164–71. https://doi.org/10.1124/dmd.108.026088.CrossRefPubMed

19.

O’Hare M, Esquiva G, McGahon MK, et al. Loss of TRPV2-mediated blood flow autoregulation recapitulates diabetic retinopathy in rats. JCI Insight. 2022;7(18):e155128. https://doi.org/10.1172/jci.insight.155128.CrossRefPubMedPubMedCentral

20.

Hanaguri J, Yokota H, Watanabe M, et al. Retinal blood flow dysregulation precedes neural retinal dysfunction in type 2 diabetic mice. Sci Rep. 2021;11(1):18401. https://doi.org/10.1038/s41598-021-97651-3.CrossRefPubMedPubMedCentral

21.

Augustine J, Pavlou S, Harkin K, Stitt AW, Xu H, Chen M. IL-33 regulates Müller cell-mediated retinal inflammation and neurodegeneration in diabetic retinopathy. Dis Model Mech. 2023;16(9):dmm050174. https://doi.org/10.1242/dmm.050174.CrossRefPubMedPubMedCentral

22.

Toh H, Smolentsev A, Bozadjian RV, et al. Vascular changes in diabetic retinopathy-a longitudinal study in the Nile rat. Lab Invest. 2019;99(10):1547–60. https://doi.org/10.1038/s41374-019-0264-3.CrossRefPubMedPubMedCentral

23.

Kugler EC, Greenwood J, MacDonald RB. The neuro-glial-vascular unit: the role of glia in neurovascular unit formation and dysfunction. Front Cell Dev Biol. 2021;9:732820. https://doi.org/10.3389/fcell.2021.732820.CrossRefPubMedPubMedCentral

24.

Gupta N, Mansoor S, Sharma A, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013;7:4–10. https://doi.org/10.2174/1874364101307010004.CrossRefPubMedPubMedCentral

25.

Nian S, Lo ACY, Mi Y, Ren K, Yang D. Neurovascular unit in diabetic retinopathy: pathophysiological roles and potential therapeutical targets. Eye Vis (Lond). 2021;8(1):15. https://doi.org/10.1186/s40662-021-00239-1.CrossRefPubMed

26.

Arroba AI, Alcalde-Estevez E, García-Ramírez M, et al. Modulation of microglia polarization dynamics during diabetic retinopathy in db/db mice. Biochim Biophys Acta. 2016;1862(9):1663–74. https://doi.org/10.1016/j.bbadis.2016.05.024.CrossRefPubMed

27.

Santiago AR, Baptista FI, Santos PF, et al. Role of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases. Mediators Inflamm. 2014;2014:465694. https://doi.org/10.1155/2014/465694.CrossRefPubMedPubMedCentral

28.

Dixon MA, Greferath U, Fletcher EL, Jobling AI. The contribution of Microglia to the development and maturation of the Visual System. Front Cell Neurosci. 2021;15:659843. https://doi.org/10.3389/fncel.2021.659843.CrossRefPubMedPubMedCentral

29.

Guo C, Chen Q, Chen J, et al. 8-Hydroxyguanosine as a possible RNA oxidative modification marker in urine from colorectal cancer patients: evaluation by ultra performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1136:121931. https://doi.org/10.1016/j.jchromb.2019.121931.CrossRefPubMed

30.

Simó R, Hernández C, Porta M, et al. European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Effects of topically administered neuroprotective drugs in early stages of Diabetic Retinopathy: results of the EUROCONDOR Clinical Trial. Diabetes. 2019;68(2):457–63. https://doi.org/10.2337/db18-0682.CrossRefPubMed

31.

Hernández C, Arroba AI, Bogdanov P, et al. Effect of Topical Administration of Somatostatin on retinal inflammation and neurodegeneration in an experimental model of diabetes. J Clin Med. 2020;9(8):2579. https://doi.org/10.3390/jcm9082579.CrossRefPubMedPubMedCentral

32.

Zerbini G, Maestroni S, Leocani L, et al. Topical nerve growth factor prevents neurodegenerative and vascular stages of diabetic retinopathy. Front Pharmacol. 2022;13:1015522. https://doi.org/10.3389/fphar.2022.1015522.CrossRefPubMedPubMedCentral

33.

Liu Y, Leo LF, McGregor C, Grivitishvili A, Barnstable CJ, Tombran-Tink J. Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(akita) mice. Mol Med. 2012;18(1):1387–401. https://doi.org/10.2119/molmed.2012.00008.CrossRefPubMedPubMedCentral

34.

Gonçalves A, Almeida L, Silva AP, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates retinal endothelial cell dysfunction triggered by inflammation. Biomed Pharmacother. 2018;102:833–8. https://doi.org/10.1016/j.biopha.2018.03.144.CrossRefPubMed

35.

Borrelli E, Barresi C, Feo A, et al. Imaging biomarkers and clinical factors associated with the rate of progressive inner and outer retinal thinning in patients with diabetic macular edema. Sci Rep. 2023;13(1):3224. https://doi.org/10.1038/s41598-023-30432-2.CrossRefPubMedPubMedCentral

36.

Safi SZ, Qvist R, Kumar S, Batumalaie K, Ismail IS. Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. Biomed Res Int. 2014;2014:801269. https://doi.org/10.1155/2014/801269.CrossRefPubMedPubMedCentral

37.

Sachdeva MM. Retinal neurodegeneration in diabetes: an emerging Concept in Diabetic Retinopathy. Curr Diab Rep. 2021;21(12):65. https://doi.org/10.1007/s11892-021-01428-x.CrossRefPubMedPubMedCentral

38.

Carpineto P, Toto L, Aloia R, et al. Neuroretinal alterations in the early stages of diabetic retinopathy in patients with type 2 diabetes mellitus. Eye (Lond). 2016;30(5):673–9. https://doi.org/10.1038/eye.2016.13.CrossRefPubMed

39.

van Dijk HW, Verbraak FD, Kok PH, et al. Early neurodegeneration in the retina of type 2 diabetic patients. Invest Ophthalmol Vis Sci. 2012;53(6):2715–9. https://doi.org/10.1167/iovs.11-8997.CrossRefPubMedPubMedCentral

40.

Nagata A, Omachi K, Higashide T, et al. OCT evaluation of neuroprotective effects of tafluprost on retinal injury after intravitreal injection of endothelin-1 in the rat eye. Invest Ophthalmol Vis Sci. 2014;55(2):1040–7. https://doi.org/10.1167/iovs.13-13056.CrossRefPubMed

41.

Li H, Zhang J, Lin L, Xu L. (2019) Vascular protection of DPP-4 inhibitors in retinal endothelial cells in in vitro culture. Int Immunopharmacol 2019 66:162–168. https://doi.org/10.1016/j.intimp.2018.10.040

42.

Xu Z, Wei Y, Gong J, et al. NRF2 plays a protective role in diabetic retinopathy in mice. Diabetologia. 2014;57(1):204–13. https://doi.org/10.1007/s00125-013-3093-8.CrossRefPubMed

43.

Albert-Garay JS, Riesgo-Escovar JR, Sánchez-Chávez G, Salceda R. Retinal Nrf2 expression in normal and early streptozotocin-diabetic rats. Neurochem Int. 2021;145:105007. https://doi.org/10.1016/j.neuint.2021.105007.CrossRefPubMed

44.

Li H, Seo MS, An JR, et al. Dipeptidyl peptidase-4 inhibitor sitagliptin induces vasorelaxation via the activation of Kv channels and PKA. Toxicol Appl Pharmacol. 2019;384:114799. https://doi.org/10.1016/j.taap.2019.114799.CrossRefPubMed

45.

Ayaori M, Iwakami N, Uto-Kondo H, et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc. 2013;2(1):e003277. https://doi.org/10.1161/JAHA.112.003277.CrossRefPubMedPubMedCentral

46.

Eshaq RS, Wright WS, Harris NR. Oxygen delivery, consumption, and conversion to reactive oxygen species in experimental models of diabetic retinopathy. Redox Biol. 2014;2:661–6. https://doi.org/10.1016/j.redox.2014.04.006.CrossRefPubMedPubMedCentral

47.

Ding X, Zhang M, Gu R, Xu G, Wu H. Activated microglia induce the production of reactive oxygen species and promote apoptosis of co-cultured retinal microvascular pericytes. Graefes Arch Clin Exp Ophthalmol. 2017;255(4):777–88. https://doi.org/10.1007/s00417-016-3578-5.CrossRefPubMed

48.

Carpi-Santos R, de Melo Reis RA, Gomes FCA, Calaza KC. Contribution of Müller cells in the Diabetic Retinopathy Development: focus on oxidative stress and inflammation. Antioxid (Basel). 2022;11(4):617. https://doi.org/10.3390/antiox11040617.CrossRef

49.

Germer A, Jahnke C, Mack A, Enzmann V, Reichenbach A. Modification of glutamine synthetase expression by mammalian Müller (glial) cells in retinal organ cultures. NeuroReport. 1997;8(14):3067–72. https://doi.org/10.1097/00001756-199709290-00012.CrossRefPubMed

50.

Li B, Ning B, Yang F, Guo C. Nerve growth factor promotes retinal neurovascular unit repair: a review. Curr Eye Res. 2022;47(8):1095–105. https://doi.org/10.1080/02713683.2022.2055084.CrossRefPubMed

51.

Wareham LK, Calkins DJ. The neurovascular unit in Glaucomatous Neurodegeneration. Front Cell Dev Biol. 2020;16(8):452. https://doi.org/10.3389/fcell.2020.00452.CrossRef

52.

Xia F, Ha Y, Shi S, et al. Early alterations of neurovascular unit in the retina in mouse models of tauopathy. Acta Neuropathol Commun. 2021;9:51. https://doi.org/10.1186/s40478-021-01149-y.CrossRefPubMedPubMedCentral

53.

Moreno-Ramos T, Benito-León J, Villarejo A, Bermejo-Pareja F. Retinal nerve fiber layer thinning in dementia associated with Parkinson’s disease, dementia with Lewy bodies, and Alzheimer’s disease. J Alzheimers Dis. 2013;34(3):659–64.CrossRefPubMed

54.

Angelopoulou E, Piperi C. DPP-4 inhibitors: a promising therapeutic approach against Alzheimer’s disease. Ann Transl Med. 2018;6:255–255. https://doi.org/10.21037/atm.2018.04.41.CrossRefPubMedPubMedCentral

Title: Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2+/− rat model
Authors: Hugo Ramos
Josy Augustine
Burak M. Karan
Cristina Hernández
Alan W. Stitt
Tim M. Curtis
Rafael Simó
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: Journal of Neuroinflammation / Issue 1/2024
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-024-03283-5

Dysregulated expression of miR-140 and miR-122 compromised microglial chemotaxis and led to reduced restriction of AD pathology

Open Access
Alzheimer's Disease
Original Research

Astrocytic DLL4-NOTCH1 signaling pathway promotes neuroinflammation via the IL-6-STAT3 axis

Open Access
Original Research

SPOCK2 modulates neuropathic pain by interacting with MT1-MMP to regulate astrocytic MMP-2 activation in rats with chronic constriction injury

Open Access
Neuropathic Pain
Original Research

Hypoxia inducible factor-1α regulates microglial innate immune memory and the pathology of Parkinson’s disease

Open Access
Parkinson Disease
Original Research

Metabolic-driven analytics of traumatic brain injury and neuroprotection by ethyl pyruvate

Open Access
Research

CSF1R antagonism results in increased supraspinal infiltration in EAE

Open Access
Original Research

Keynote series | Spotlight on menopause

Springer Medicine

Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2+/− rat model

Unlock free access to practice-relevant journal articles

Looking for something specific?

About journals on Springer Medicine

Abstract

Please log in to get access to this content